- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03097666
Evaluation of Safety and Dose Response Using C2 CryoBalloon™ Swipe Ablation System for Barrett's Esophagus
Clinical Trial to Evaluate Safety and Dose Response Using the C2 CryoBalloon™ Swipe Ablation System for the Treatment of Barrett's Esophagus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The procedure will be performed on an outpatient basis, and the CryoBalloon Swipe will be used for all ablations following the instructions for use provided with the product.
Patients who meet the eligibility criteria will be assigned to one of the treatment groups and doses, depending on the order of their enrollment:
In phase I, the first 6 patients will be treated with Dose 1 (lowest).
All patients will have to undergo 8 week (±1 week) follow-up EGD to evaluate efficacy of the dose before the study continues.
If the follow-up endoscopies show that Dose 1 eradicates ≥80% of the treated BE (by median percentage) and no SAE's are reported, this dose is defined as the therapeutic dose and enrollment will proceed to phase II.
If Dose 1 eradicates <80% of the treated BE, enrollment in Phase I will continue at the next highest dose. Treatment doses will be escalated in this manner until the earlier of a dose-related Serious Adverse Event (SAE) or determination of the therapeutic dose based on endoscopic exam.
When the therapeutic dose is determined, the study will proceed to Phase II to generate additional safety and efficacy data.
Phase II
Phase II will confirm the safety and efficacy of the therapeutic dose found in Phase I.
---------------------------------------------------------------
Dose-related SAEs include pain in the treatment area greater than 6 (on VAS) on 24 hours and seven (7) days post-treatment; symptomatic stricture requiring an additional EGD with endoscopic dilation before the first follow-up EGD; symptomatic stricture at follow-up EGD; or any stricture (symptomatic or asymptomatic) preventing passage of the diagnostic endoscope at follow-up EGD. Any other serious adverse events within 30 days after treatment will also be evaluated by the Data and Safety Monitoring Board (DSMB) for relationship to the dose and severity.
When a Dose-related serious adverse event occurs, the Holding Rule will be invoked and enrollment at that dose will be held until the DSMB has evaluated the event.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands
- AMC Medical Research B.V.
-
Amsterdam, Netherlands
- St. Antonius Hospital Nieuwegein
-
Eindhoven, Netherlands
- Catharina Ziekenhuis te Eindhoven
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with flat-type (Paris type 0-IIb) BE esophagus, with an indication for ablation therapy, meaning:
- Diagnosis of LGD or HGD in BE (confirmed by baseline histopathological analysis), OR
- Residual BE with any grade of dysplasia after endoscopic resection
- Prague Classification Score C≤3
- Patients should be ablative-naïve (no previous ablation therapy of the esophagus)
- Older than 18 years of age at time of consent
- Operable per institution's standards
- Provides written informed consent on the IRB-approved informed consent form
- Willing and able to comply with follow-up requirements
Exclusion Criteria:
- Esophageal stenosis or stricture preventing advancement of a therapeutic endoscope.
- Any endoscopically visualized lesion such as ulcers, masses or nodules.
- History of locally advanced (>T1a) esophageal cancer
- History of esophageal varices
- Prior distal esophagectomy
- Active esophagitis LA grade B or higher
- Severe medical comorbidities precluding endoscopy
- Uncontrolled coagulopathy
- Pregnant or planning to become pregnant during period of study
- Patient refuses or is unable to provide written informed consent
- Participation in another study with investigational drug within the 30 days preceding or during the present study
- General poor health, multiple co-morbidities placing the patient at risk or otherwise unsuitable for trial participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: C2 Cryoballoon Swipe Ablation System
|
The C2 CryoBalloon Swipe Ablation System ("CryoBalloon Swipe") is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-related SAEs
Time Frame: 30 days
|
Safety will be evaluated by the incidence of Dose-related SAEs.
Dose-related SAEs include pain in the treatment area, or any stricture (symptomatic or asymptomatic) preventing passage of the diagnostic endoscope at follow-up EGD.
|
30 days
|
Efficacy: Percent Eradication by therapeutic dose
Time Frame: 8 weeks
|
Eradication percentage of BE confirmed by histological evidence of eradication of BE, after treatment with the therapeutic dose.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of AEs
Time Frame: up to 30 days post-treatment
|
Incidence of all serious and non-serious adverse events up to 30 days post-treatment.
|
up to 30 days post-treatment
|
Post-procedure pain
Time Frame: 24 hours and 7 days post-procedure
|
Post-procedure pain in the area of the cryoablation treatment (scored on a 0 to 10 point VAS)
|
24 hours and 7 days post-procedure
|
Efficacy: Percent Regression
Time Frame: 8 weeks
|
Regression percentage at the first follow-up endoscopy, after 1 treatment with the therapeutic dose.
|
8 weeks
|
Efficacy: Treatment
Time Frame: 8 weeks
|
Efficacy of treatment with CryoBalloon Swipe ablation system, defined as the proportion of patients with ≥80% regression of BE after 1 treatment.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-0018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Barrett Esophagus
-
Erbe Elektromedizin GmbHNAMSA; Kansas City Veteran Affairs Medical Center; Erbe USA IncorporatedTerminatedBarrett's Esophagus | High-grade Dysplasia in Barrett Esophagus | Low Grade Dysplasia in Barrett EsophagusUnited States
-
University Medical Center GroningenCompletedEsophageal Cancer | Barrett Esophagus | Dysplasia in Barrett EsophagusNetherlands
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedBarrett Esophagus | Barrett AdenocarcinomaNetherlands
-
Mayo ClinicTerminatedBarretts Esophagus With High Grade Dysplasia | Barrett AdenocarcinomaUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina... and other collaboratorsNot yet recruitingEsophageal Cancer | Barrett Adenocarcinoma | Barretts Esophagus With Dysplasia
-
Portsmouth Hospitals NHS TrustUniversity of PortsmouthUnknownBarrett Esophagus | Barrett Adenocarcinoma | Barrett Metaplasia | Barrett Oesophagitis With DysplasiaUnited Kingdom
-
Professor Michael BourkeWithdrawn
-
Lucid Diagnostics, Inc.RecruitingBarrett Esophagus | Barretts Esophagus With Dysplasia | Esophagus AdenocarcinomaUnited States
-
Medical University of South CarolinaCompletedBarretts Esophagus With DysplasiaUnited States
-
Allegheny Singer Research Institute (also known...Integra LifeSciences CorporationTerminatedBarrett Esophagus | High Grade Dysplasia | EsophagusUnited States
Clinical Trials on C2 CRYOBALLOON SWIPE ABLATION SYSTEM
-
Pentax MedicalCompletedEsophageal CancerUnited States
-
Pentax MedicalCompletedBarrett's EsophagusNetherlands
-
Pentax MedicalCompletedEsophageal Squamous Cell DysplasiaChina
-
Pentax MedicalEnrolling by invitation
-
Koen MuntersPentax MedicalRecruitingBarrett's Esophagus | Cryotherapy | Ablation Therapy | Cryoballoon AblationNetherlands
-
Pentax MedicalCompletedBarrett's EsophagusUnited States, Netherlands
-
Pentax MedicalCompletedEsophageal CancerNetherlands
-
Staten Island University HospitalUnknownPersistent Atrial FibrillationUnited States
-
Pentax MedicalActive, not recruitingBarrett EsophagusUnited States
-
Pentax MedicalCompletedEsophageal Cancer | Barrett's EsophagusUnited States, Netherlands